17c起草视频

Marseille, France, November 12, 2024 鈥� 17c起草视频, a biotech company focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr. Klara Owen as Chief Medical Officer.

鈥淚 am delighted to welcome Dr. Owen to 17c起草视频. Her experience in T1D and metabolic diseases in general, from clinical translation to Phase 3, will be fundamental for the development of DGX-01, our lead candidate, through the clinical and regulatory processes,鈥� said Benjamin Charles, CEO of 17c起草视频.

鈥淔urthermore, Dr. Owen鈥檚 career spans from clinical practice to medical director for pharma and biotech companies. She is a great addition to our team, to support 17c起草视频鈥檚 growth and our ambition to change the treatment paradigm in diabetes.鈥�

The company鈥檚 lead candidate, DGX-01, is a first-in-class recombinant protein that aims at replicating insulin-producing beta cells in the pancreas. This novel approach has the potential to offer a disease-modifying therapy for T1D, a chronic and life-threatening condition that affects millions of people worldwide. It is currently undergoing IND-enabling studies and is expected to enter clinical trials in 2026.